Management of Conjunctivitis and Bronchitis in Rituximab-Treated Patients
Treat both conditions promptly with standard antimicrobial therapy while continuing rituximab, but maintain heightened vigilance for severe or recurrent infections that may require temporary drug discontinuation.
Conjunctivitis Management
Initial Assessment and Treatment
Continue rituximab during acute conjunctivitis episodes unless severe infection develops. The FDA label documents conjunctivitis as a recognized adverse reaction occurring in 5% of pemphigus vulgaris patients treated with rituximab 1. However, this represents primarily mild inflammatory conjunctivitis rather than infectious disease requiring drug cessation.
For infectious conjunctivitis:
- Initiate appropriate topical antibiotics (fluoroquinolones for bacterial, supportive care for viral)
- Use preservative-free formulations when possible to minimize additional irritation
- Add topical corticosteroids cautiously only after ruling out viral keratitis, particularly in immunosuppressed patients
- Monitor closely for progression to more severe ocular surface disease
Critical Distinction: Drug-Related vs. Infectious
Rituximab can cause chronic conjunctivitis as a direct adverse effect 2. One documented case showed severe bilateral conjunctivitis developing 3-4 weeks post-rituximab induction, resolving within 2 months after drug cessation 2. If conjunctivitis is:
- Persistent despite antimicrobial therapy
- Bilateral and symmetric
- Associated with other rituximab adverse effects
- Temporally related to infusions
Consider rituximab-induced conjunctivitis and consult ophthalmology for evaluation.
When to Hold Rituximab for Ocular Disease
Discontinue rituximab only if:
- Severe infectious keratitis develops with corneal involvement
- Progressive cicatricial changes occur (though paradoxically, rituximab treats severe cicatricial pemphigoid 3, 4, 5)
- Hypogammaglobulinemia-related recurrent infections emerge
Bronchitis Management
Standard Treatment Approach
Treat bronchitis with standard antimicrobial therapy while continuing rituximab in most cases. The British Thoracic Society guidelines note that rituximab-treated patients with bronchiectasis have infection risks but do not mandate routine drug cessation for acute bronchitis 6.
For acute bronchitis:
- Viral bronchitis: Supportive care, bronchodilators if needed
- Bacterial bronchitis: Appropriate antibiotics (amoxicillin-clavulanate, doxycycline, or macrolides)
- Monitor for progression to pneumonia or bronchiectasis
High-Risk Scenarios Requiring Drug Modification
Consider holding rituximab if:
- Recurrent respiratory infections (≥3 episodes within 6 months)
- Documented hypogammaglobulinemia (IgG <6 g/L) 7
- Development of bronchiectasis on imaging 8
- Severe pneumonia requiring hospitalization
The FDA label specifically warns about serious infections including bronchitis, with 37% of pemphigus patients experiencing treatment-related infections 1. Rituximab causes prolonged B-cell depletion and hypogammaglobulinemia in 16-34% of patients 7, 1.
Monitoring Protocol for Respiratory Complications
Obtain baseline and periodic monitoring:
- Immunoglobulin levels (IgG, IgM, IgA) every 3-6 months
- Chest imaging if persistent cough develops (>4 weeks)
- Pulmonary function tests if dyspnea or recurrent infections occur
A pediatric case demonstrated reversible rituximab-induced bronchiectasis that completely resolved after drug cessation and IVIG therapy 8. This emphasizes the importance of early recognition.
Infection Prevention Strategies
Prophylaxis Considerations
Implement prophylaxis based on risk stratification:
- PCP prophylaxis: Strongly recommended during rituximab treatment and for ≥6 months after the last dose 1
- IVIG replacement: Consider if IgG <400-600 mg/dL with recurrent infections 8
- Vaccination timing: Administer pneumococcal and influenza vaccines when next rituximab dose is due, then delay rituximab for 2 weeks post-vaccination 9
Critical Pitfall to Avoid
Do not assume all respiratory symptoms are infectious. Rituximab causes rare but serious pulmonary toxicity including:
- Bronchiolitis obliterans organizing pneumonia (BOOP) 10
- Interstitial lung disease 11
- Drug-related pneumonitis (4% incidence in some populations) 11
If bronchitis symptoms persist despite appropriate antibiotics, or if dyspnea and hypoxia develop, obtain high-resolution chest CT to evaluate for drug-induced pulmonary disease rather than infection.
When to Resume Rituximab
After infection resolution:
- Wait 2-4 weeks after complete symptom resolution
- Verify adequate immunoglobulin levels if previously low
- Consider dose reduction or interval extension if recurrent infections occur
- Restart at 50% infusion rate to minimize infusion reactions 12
Special Populations
For patients with pre-existing bronchiectasis or autoimmune disease requiring rituximab 6:
- Maintain aggressive airway clearance therapy
- Use azithromycin prophylaxis (250 mg three times weekly) for chronic suppurative lung disease 8
- Monitor more frequently (every 2-3 months) for infection
The risk-benefit calculation favors continuing rituximab for severe autoimmune disease while managing infections aggressively, rather than stopping immunosuppression and risking disease flare.